Financial Results for the quarter and year ended 31st March, 2026

Net loss reportedEBITDA margin compressionExceptional itemEmphasis of matterResults View source PDF Explain this filing

AKUMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.5%Reaction day

₹540.00

prior close

₹513.70

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.2%-1.8% vs market

Pharmaceuticals peers, median of 161sector+0.4%-1.9% vs sector

On the reaction day the stock moved 1.8 pts less than Nifty Microcap 250 and 1.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.6

10m

+3.6

15m

+4.0

30m

+3.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.5+0.2-1.8+0.4-1.9

Next day

-4.3-0.1-4.2+0.1-4.4

-4.8-1.5-3.3-0.4-4.4

-3.7-1.0-2.7+0.0-3.8

-5.1-0.4-4.6+1.2-6.3

-3.1+0.6-3.7+2.1-5.1

-3.5+2.3-5.8+1.1-4.6

15d

+2.4+3.5-1.1+1.4+1.0

+14.6+5.6+9.1+2.2+12.4

+27.2+9.5+17.7+7.9+19.3

+34.2+13.3+21.0+8.1+26.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 161Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Akums Drugs and Pharmaceuticals reported FY26 standalone revenue of ₹13,487 million, up just 2.8% from ₹13,118 million in FY25. Profit after tax fell sharply to ₹1,116 million from ₹1,610 million — a decline of about 31% year-on-year. EBITDA margin compressed significantly to ~10% from ~14.5% previously. The company recognized ₹65.19 million in exceptional items comprising ₹52.32 million for changes under new labour codes and ₹12.87 million for retrospective VDA arrears. Auditors Walker Chandiok & Co. LLP issued an unmodified opinion but included an Emphasis of Matter regarding an Income Tax Department search and seizure operation conducted in January 2025; the company has received show cause notices and the financial impact remains unascertained. The board recommended a final dividend of ₹1 and a special dividend of ₹2 per share.

Likely market impact

The sharp PAT decline and margin compression are concerning signals despite flat revenue growth. The ongoing Income Tax Department proceedings add regulatory uncertainty. The dividend payout provides some investor comfort.